Molecular Partners to Present at Upcoming Healthcare Investor Conferences

Rhea-AI Summary

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 25, 2022 – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech firm, announced CEO Patrick Amstutz's participation in two investor events in March 2022. Key dates include the Credit Suisse London Global Healthcare Conference on March 1-2, and a Fireside chat at the Cowen Health Care Conference on March 9. Additionally, the FY 2021 annual report will be published on March 15, followed by an investor conference call on March 16. Webcasted presentations will be accessible via the company's website.

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 25, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in two upcoming healthcare investor events in March, 2022. In addition, the Company will publish its full year 2021 annual report on March 15 and hold an investor conference call on March 16, 2021.

Presentation Details:

Cowen Health Care Conference – Fireside chat

• Wednesday, March 9, 2022 at 2:10-2:40pm ET
  

Conference Participation Details:

Credit Suisse London Global Healthcare Conference

• Tuesday, March 1, 2022 to Wednesday, March 2, 2022
  

Webcasted presentations will be made available through the Molecular Partners website.

Financial calendar
March 15, 2022	Publication of FY 2021 Annual report and audited 2021 results
April 13, 2022	Annual General Meeting
Conference call details
Date and Time:	March 16, 2021 at 8am ET
US/CANADA toll-free dial-in number:	(844) 865-3856
Switzerland dial-in number:	0800836507
Conference ID:	5295679

About Molecular Partners AG
Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of infectious disease, oncology, and ophthalmology, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com; Find us on Twitter - @MolecularPrtnrs 

For further details, please contact:
Seth Lewis
seth.lewis@molecularpartners.com
Tel: +1 781 420 2361 

Shai Biran, Ph.D. 
shai.biran@molecularpartners.com
Tel: +1 978 254 6286 

Thomas Schneckenburger, European IR & Media 
thomas.schneckenburger@molecularpartners.com
Tel: +41 79 407 9952 

FAQ

When will Molecular Partners publish its FY 2021 annual report?

Molecular Partners will publish its FY 2021 annual report on March 15, 2022.

What events will Molecular Partners' CEO participate in March 2022?

CEO Patrick Amstutz will participate in the Credit Suisse London Global Healthcare Conference and the Cowen Health Care Conference in March 2022.

What is the date of the investor conference call for Molecular Partners?

The investor conference call for Molecular Partners is scheduled for March 16, 2022, at 8 AM ET.

What is the significance of DARPin therapeutics developed by Molecular Partners?

DARPin therapeutics are a new class of custom-built protein drugs aimed at addressing challenges that existing treatments cannot.

Where can I find the webcasted presentations for Molecular Partners' events?

Webcasted presentations will be available on the Molecular Partners website.